University of Hertfordshire

View graph of relations
Original languageEnglish
Article number16649852
Number of pages20
JournalEuropean Journal of Haematology
Early online date27 Dec 2019
DOIs
Publication statusE-pub ahead of print - 27 Dec 2019

Abstract

INTRODUCTION: Currently recommended patient-reported outcome (PRO) measures for patients with pyruvate kinase (PK) deficiency are non-disease-specific. The PK Deficiency Diary (PKDD) and PK Deficiency Impact Assessment (PKDIA) were developed to be more targeted measures for capturing the symptoms and impacts of interest to this patient population. METHODS: The instruments were developed based on concept elicitation interviews with 21 adults and modified based on 20 cognitive interviews. The domain structure and item concepts of the PKDD and PKDIA were compared to currently recommended measures, the EORTC QLQ-C30 and the SF-36v2®. RESULTS: The PKDD is a 7-item measure of the core signs and symptoms of PK deficiency. The PKDIA is a 14-item measure of the impacts of PK deficiency on patients’ health-related quality of life (HRQoL). Minimal similarities were found between the new measures and the EORTC QLQ-C30 (e.g. 43% of concepts were similar to the PKDD; 42% were similar to the PKDIA) and SF-36v2® (57% of concepts were similar to the PKDD; 17% were similar to the PKDIA). CONCLUSIONS: The PKDD and PKDIA fill a gap in the existing outcomes measurement strategy for PK deficiency. Future work includes psychometric evaluation of these newly developed measures.

Notes

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.

ID: 19411315